Biologic therapy in psoriasis patients with current or previous solid tumor malignancy: A systematic review

Psoriasis is a helper T cell 17-driven chronic inflammatory disease.​ Although targeted biologics revolutionized management, the utility and safety of biologics in psoriasis patients with current or previous solid tumor malignancy (PPM) remains uncertain.​​ This systematic review investigates evidence surrounding this indication.

银屑病（Psoriasis）是一种由辅助性T细胞17（helper T cell 17）驱动的慢性炎症性疾病。尽管靶向生物制剂已革新了银屑病的临床诊疗管理方案，但此类生物制剂在现患或既往合并实体恶性肿瘤的银屑病患者（PPM）中的临床效用与安全性仍未明确。本项系统综述旨在围绕该临床适应证开展相关证据调研。